Reported Q: Q2 2025 Rev YoY: -1,157.1% EPS YoY: -81.8% Move: +0.97%
Ares Commercial Real
ACRE
$5.21 0.97%
Exchange NYSE Sector Real Estate Industry REIT Mortgage
Q2 2025
Published: Aug 5, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for ACRE

Reported

Report Date

Aug 5, 2025

Quarter Q2 2025

Revenue

-4.33M

YoY: -1,157.1%

EPS

-0.20

YoY: -81.8%

Market Move

+0.97%

Previous quarter: Q1 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • EPS of $-0.20 decreased by 81.8% from previous year
  • Gross margin of 262.9%
  • Net income of -11.04M
  • "During the second quarter, we reduced our office loans to $524 million, a decrease of 10% quarter-over-quarter and a decrease of 30% year-over-year. This decrease was driven by repayments, active asset management and the decision to accelerate resolutions. There are no remaining loans in the portfolio collateralized with properties that are primarily used for life sciences." - Bryan Patrick Donohoe
ACRE
Company ACRE

Executive Summary

Ares Commercial Real Estate Corporation (ACRE) delivered a quarter characterized by disciplined balance sheet optimization and portfolio repositioning aimed at restoring earnings power in a higher-rate, constrained office environment. The company reported a GAAP net loss of approximately $11 million for Q2 2025 and distributable earnings (DE) of about -$28 million, which includes a $33 million realized loss on the exit of a Massachusetts office life sciences loan. Excluding the life sciences exit, DE was approximately $5 million ($0.09 per diluted share), underscoring the near-term earnings drag from nonaccruals and high-risk assets but the potential for improvement as resolutions advance and new loan origination accelerates. Management highlighted a decisive portfolio shift: office loan exposures declined 10% QoQ to $524 million (down 30% YoY), life-science collateral was exited, and the portfolio now has no remaining life-science collateral. As of June 30, 2025, risk-rated 4 and 5 loans remained at 5 loans with two positions comprising about 75% of the outstanding balance, signaling continued concentration risk even as the firm advances resolutions and originations. The balance sheet benefits are evident: net debt-to-equity (excluding CECL) held at 1.2x, borrowings reduced to $889 million (down 6% QoQ, 39% YoY), and unfunded commitments materially lower at $37 million (down 50% QoQ, 58% YoY). Importantly, management signaled a return to growth through higher origination activity, supported by an expanded Ares platform, and a first-post-quarter commitment cycle featuring 4 self-storage loans totaling $43 million. The board affirmed a quarterly cash dividend of $0.15 per share for 3Q25, yielding a double-digit implied return given the prevailing price levels. Looking ahead, management anticipates origination momentum to build in 3Q and beyond, with the portfolio expected to be at or above the current size over the next 12 months, implying a gradual rebuild in earnings and dividend coverage as resolutions progress and new loans fund growth. Overall, the results reflect a deliberate reset toward lower-risk, higher-visibility cash flow while maintaining optionality to deploy capital into attractive opportunities as market conditions stabilize and volumes improve.

Key Performance Indicators

Revenue
Decreasing
-4.33M
QoQ: -128.99% | YoY: -1 157.07%
Gross Profit
Decreasing
-11.39M
2.63% margin
QoQ: -176.21% | YoY: -2 878.54%
Operating Income
Stable
5.07M
QoQ: N/A | YoY: N/A
Net Income
Decreasing
-11.04M
QoQ: -218.08% | YoY: -80.16%
EPS
Decreasing
-0.20
QoQ: -217.65% | YoY: -81.82%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 14.11 0.08 +29.6% View
Q2 2025 -4.33 -0.20 -1.0% View
Q1 2025 14.95 0.17 +157.4% View
Q4 2024 -0.49 -0.20 -101.0% View
Q3 2024 10.89 -0.11 -54.4% View